Hepatocyte growth factors market to grow to $141m by 2034

An increase in liver diseases will drive the growth of the market

The global hepatocyte growth factors (HGFs) market will reach $141m by 2034, up from $70.3m in 2023, at a compound annual growth rate (CAGR) of 6.5%.

Transparency Market Research said the increasing prevalence of liver diseases and the rising number of surgical operations that demand effective and painless wound-healing solutions will drive the sector's expansion.

Also contributing to the market's growth are strategic collaborations that focus on driving innovation and accelerating the development of new HGF-based therapies.

Despite growth prospects, high development costs and stringent regulatory requirements may limit the market's potential.

“Ensuring the safety and efficacy of HGF-based therapies remains a critical concern, necessitating rigorous clinical trials and comprehensive safety assessments,” the report said.